Andolast
Andolast (CR 2039) is an anti-allergic agent. Andolast can inhibit cAMP-phosphodiesterase with an IC50 value of 50 μM. Andolast can be used for the research of asthma[1].
Product Specifications
CAS Number
143330-46-5
Product Name Alternative
CR 2039; Dizolast
UNSPSC
12352005
Target
Phosphodiesterase (PDE)
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/andolast.html
Solubility
DMSO : 11.36 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C(C1=CC=C(C2=NN=NN2)C=C1)NC3=CC=C(C4=NN=NN4)C=C3.[Na].[Na]
Molecular Formula
C15H11N9Na2O
Molecular Weight
379.29
References & Citations
[1]Revel L, Colombo S, Ferrari F, Folco G, Rovati LC, Makovec F. CR 2039, a new bis- (1H-tetrazol-5-yl) phenylbenzamide derivative with potential for the topical treatment of asthma. Eur J Pharmacol. 1992;229 (1) :45-53.|[2]Czuczwar SJ, Gasior M, Kozicka M, Pietrasiewicz T, Turski WA, Kleinrok Z. A potential anti-asthmatic drug, CR 2039, enhances the anticonvulsive activity of some antiepileptic drugs against pentetrazol in mice. Eur Neuropsychopharmacol. 1998;8 (3) :233-238.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
